DOI:
10.1055/s-00000004
Aktuelle Neurologie
Ausgabe S 1 ·
Volume 19 ·
September 1992
DOI: 10.1055/s-002-9553
S1
Krämer, G.;
Schmidt, D.;
Stefan, H.;
Hanefeld, F.:
S2
Schmidt, D.:
Why do we Need New Antiepileptic Drugs?
S4
Persson, L.:
Role of GABA in Epilepsy. Evidence for the Specifity of the Action of Vigabatrin
S7
Haegele, K. D.:
Vigabatrin: Design and Development of a Rationally Conceived Drug
S12
Zahner, B.;
Stefan, H.:
Neuropathology and Neurophysiology of Vigabatrin
S17
Hanefeld, F.:
Effectivity and Tolerability of Vigabatrin in Childhood and Adolescence
S21
Dulac, O.:
Vigabatrin in Refractory Infantile Spasms
S23
Schmitz-Moormann, W.;
Kruse, R.:
Vigabatrin Long-term Therapy in Symptomatic Epilepsies with Complex Focal Seizures in Pediatrics
S26
Auerswald, G.:
Vigabatrin in Therapy Resistant Childhood Epilepsy
S28
Krämer, G.:
Vigabatrin: Efficacy and Tolerability in Epilepsies of Adults
S41
Ried, S.;
Schmidt, D.:
Vigabatrin in Patients with Refractory Focal Epilepsy - Our Clinical Experience
S46
Thümler, R.;
Krämer, G.;
Besser, R.:
Vigabatrin: Long-term Efficacy and Tolerability in Drug-resistent Epilepsy
S48
Fröscher, W.;
Rauber, A.;
Rothmeier, J.;
Steinert, T.:
Vigabatrin in Drug Resistant Epilepsies
S50
Otto, F. G.;
Egli, M.:
Effect of Vigabatrin on Partial Seizures of Different Origin
S52
Haan, J.;
Kauerz, U.:
Vigabatrin in Therapy Resistant Epilepsy: Efficacy and Long-Term Follow-Up
S54
Blankenhorn, V.:
Vigabatrin in Therapy-Refractory Symptomatic Focal Epilepsies of Adults in the Epilepsy Center Kehl-Kork
S56
Riekkinen, P.:
Cognitive Profile of Vigabatrin
